2Nagaretani H, Nakamura T, Funahashi T, et al. Visceral fat is a major contributor for multiple risk factor clustering in Japanese men with impaired glucose tolerance[J]. Diabetes Care, 2001, 24(12): 2127.
3Richard L, Atkinson D. Guidelines for the initiation of obesity treatment [J]. J Nutr Biochem, 1998, 9(10): 546.
4Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults [J]. Arch Intern Med, 2000, 160(9): 1321.
5Philip W, James T, Arne A, et al. Effect of sibutramine of weight maintanance initiation of obesity treatment after weight loss: a randomized trial[J]. Lancet, 2000, 365(9248): 2119.
6Zachary T, Bloomgarden E. New insights in obesity[J]. Diabetes Care, 2002, 25(4):789.
7Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subject:effect of drastic weight loss after gastroplasty[J]. Int J Obes Relat Metab Disord, 1998, 22(3): 222.
8Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity[J]. Obes Res, 2000, 8(1):49.
9Hollander PA, Elbein SC , Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study[J]. Diabetes Care, 1998, 21(8): 1288.
10Wadden TA, Berkowitz RI, Womble LG, et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone. A placebo-controlled trial[J]. Obes Res, 2000, 8(6): 431.
